Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Important paper from Japan published in Blood.
The authors have developed FVIII variants with increased specific activity, which can potentially be used for gene therapy in hemophilia A.
These would be the equivalent of the Padua variant for FIX and can be used at much lower doses.
Even when used at 1/30th of the dose of Roctavian in macaques, supraphysiological FVIII levels were achieved.
No human studies yet.”
Read the full article here.
Article: Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Authors: Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J. S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 30, 2026, 14:28Jennifer Le Mac: How the Immune System Shapes Venous Thrombosis
-
Apr 30, 2026, 14:22Samantha Xavier: Successfully Defended My PhD Thesis on P-Selectin as a Biomarker for Venous Thromboembolism
-
Apr 30, 2026, 14:09Robert Lufkin: Anti-Amyloid Drugs Fail Alzheimer’s Patients
-
Apr 30, 2026, 13:54Matthew D. Neal: A Major Step Forward in Trauma and Resuscitation Science
-
Apr 30, 2026, 13:35Day 2 of the EHC Youth Leadership Workshop 2026
-
Apr 30, 2026, 13:23The Gap Between Clinical Assessment and Patient Experience in VTE – RPTH Journal
-
Apr 30, 2026, 13:17Low Absolute Neutrophil Count Doesn’t Always Indicate Pathology – ASH Education
-
Apr 30, 2026, 13:01William Aird: When Inducers Make DOACs Fail
-
Apr 30, 2026, 12:56Abdul Muqtadir Abbasi: HIT Management – Avoid Platelet Transfusion